BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T154320
CREATED:20201022T101624Z
LAST-MODIFIED:20201022T104507Z
UID:27586-1612828800-1613087999@www.pharmajournalist.com
SUMMARY:Gene Therapy Medical Affairs
DESCRIPTION:The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. \nIndustry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy\, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies. \n \nJoin this definitive\, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nThis virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement\, discussion\, and Q&A’s in order for you to get the best value from this meeting. \nTo know more about Gene Therapy Medical Affairs please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-medical-affairs/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T154320
CREATED:20201001T101330Z
LAST-MODIFIED:20201019T092845Z
UID:27319-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:RNA Therapeutics 2021
DESCRIPTION:Innovations in technologies and applications of RNA-based medicine \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. Furthermore\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, have triggered a major expansion of the RNA-therapeutics field. \nThe 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies\, oligonucleotide delivery\, therapeutic applications and future trends and innovations. \n \nJoin us in February 2021\, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry\, upcoming regulatory updates and industry implications. \nBENEFITS OF ATTENDING:  \n\nExplore in industry insights into how mRNA is being used to combat COVID-19\nEngage in case studies exploring the growing therapeutic potential of RNA for rare diseases\nDelve into future trends in AI application for optimal RNA therapeutics\nHear regulatory outlooks of the RNA landscape\, clinical trials and looking ahead\n\nView the full agenda and speaker line-up online: www.therapeutics-rna.com/pjwl \nFocus day on RNA Interference – 12TH February 2021\n\nAs the industry of RNA therapeutics advances this year’s focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome\, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery\, and targeted delivery of nucleic acid therapeutics. Furthermore\, this year’s focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry. \nEARLY-BIRD RATES:  \n\nBOOK BY 30TH OCTOBER AND SAVE £400\nBOOK BY 30TH NOVEMBER AND SAVE £200\nBOOK BY 11TH DECEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.therapeutics-rna.com/pjwl \nChairs for 2021: \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFocus Day Chair for 2021: Shalini Andersson\, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery\, AstraZeneca \nFeatured speakers:  \n\nDong Yu\, Fellow\, Senior Director\, and Head\, GSK Vaccines\nMaria Luisa Pineda\, CEO and Co-Founder\, Envisagenics\nKirsty Wydenbach\, Deputy Unit Manager/Senior Medical Assessor\, MHRA\nDong Ki Lee\, CEO\, OliX\nJennifer Pluim\, Vice President Medical Affairs\, ProQR\nArpan Desai\, Team Leader\, Advanced Drug Delivery\, Pharmaceutical Sciences\, AstraZeneca\nRuchi Shah\, Senior Research Engineer\, New Therapeutics Modalities\, Eli Lilly and Company\nMichael Mulqueen\, Vice President Business Development\, eTheRNA immunotherapies\nTroels Koch\, Founder & CEO\, Aqiventa\n\nWho should attend: \n\nResearch & Development Directors/Managers/Scientists\nHeads of Clinical Development\nHeads of Pre-Clinical Development\nHead of RNA Biology\nHead of RNA Formulation and Drug Delivery\nHead of Pre-clinical R&D\nHead of New Modalities\nHead of Discovery\nSenior Scientists\nChief Scientific Officers\nChief Medical Officers\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nFollow us:  @SMiPharm #SMirna
URL:https://www.pharmajournalist.com/event/rna-therapeutics-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T154320
CREATED:20201012T114728Z
LAST-MODIFIED:20201012T114728Z
UID:27476-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:Sponsored by: Celvivo \nChaired by: Stefan Przyborski\, Professor of Cell Technology\, Durham University \nDeveloping Complex Physiologically Relevant Cell Models in Vitro \n3D Cell Culture is gaining momentum in the pharmaceutical industry\, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery\, predictivity and validation\, safety\, and toxicity. \n \nSMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development\, toxicity testing\, and safety assurance. In addition\, the conference will look into the newest breakthroughs in Organ Chip technology\, 3D Multicellular scaffolding\, Microphysiological Systems\, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application. \nEvent Hashtag: #SMi3DCellCulture \nHIGHLIGHTS FOR 2021 \n\nDiscover the cutting-edge technology that is changing the face of pharmaceutical drug development\nExplore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives\nInsight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro\nDiscuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery\nAssess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops\n\nFEATURED SPEAKERS INCLUDE: \n\nSuzanne Fitzpatrick\, Senior Advisor for Toxicology\, US Food and Drug Administration\nPelin Candarlioglu\, Investigator – Bioengineer/Cell Biologist\, GSK\nRobert Vries\, CEO\, Hubrecht organoid Technology\nSakshi Garg\, Lab Head\, Discovery & Development Technologies\, Merck Group\nRhiannon David\, Scientific Lead Microphysiological Systems\, AstraZeneca\nStephen J. fey\, Founder and Chief Research Officer\, CelVivo\nAlejandro Amador\, Director\, Cellular Assays and Technologies\, Incyte\nFreddy Van Goethem\, Scientific Director – Fellow\, Predictive\, Investigative\, and Translational Toxicology\, Johnson & Johnson; Janssen Pharmaceutical\nJulian Bahr\, Postdoctoral Fellow\, Oncology\, AstraZeneca\nPedro Pinto\, Laboratory Manager\, Urology\, university of Greifswald – Medical Centre\n\nView the full agenda: www.3D-cellculture.com/PJwl \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist Academia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering Solution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210213
DTSTAMP:20260515T154320
CREATED:20201109T113504Z
LAST-MODIFIED:20201109T113504Z
UID:27864-1612915200-1613174399@www.pharmajournalist.com
SUMMARY:5th Annual Liquid Biopsies for Precision Oncology Summit
DESCRIPTION:Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit! \nWith two exciting LBx approvals in 2020 and investment pouring into the industry\, these assays are primed to transform the cancer-care space. To realize these untapped opportunities\, it is essential significant sensitivity\, selectivity and analytical roadblocks are addressed to prove utility in the clinic. \n \nThe 5th Annual Liquid Biopsy for Precision Oncology Summit is a crucial date in the industry calendar\, bringing together the entire value chain of oncology drug development to hear and collaborate around the latest advancements innovating cancer detection\, diagnosis and monitoring. \nThis completely online meeting will allow you to discover how latest technologies are being applied to accurately detect and analyze circulating biomarkers earlier\, effectively monitor treatment response and selectively stratify patient populations to enable delivery of targeted therapies in a time-efficient manner. \nFrom biomarker validation through to reimbursement and regulatory\, join your drug development peers striving to translate the clinical applications of liquid biopsies into a worldwide patient reality. \nTo know more about 5th Annual Liquid Biopsies for Precision Oncology Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-annual-liquid-biopsies-for-precision-oncology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR